Determining the level of fibrosis is key in evaluating patients for HBV treatment candidacy. How, when, and why should we incorporate fibrosis assessments into clinical practice? Here’s my take.
How I incorporate family history into HBV treatment and monitoring decisions in certain clinical gray zones.
Why I consider treatment for patients with immune-tolerant chronic HBV, and where I differ from current international guidance.
When managing pregnant patients with chronic HBV, the optimal timing for prophylaxis discontinuation postpartum remains unclear. Here’s my approach.
In episode 2 of this ongoing series, listen to a conversation between Robert G. Gish, MD, FAASLD, and patient and advocate, Alan Wang, on approaches to destigmatize HBV infection and remove barriers to care.
In episode 3 of this ongoing series, listen to a conversation between Jordan J. Feld, MD, MPH, and Wendy, who is living with chronic hepatitis B, on incorporating shared decision-making to determine when to initiate treatment.
In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels.
This concise MedicalMinute presentation reviews the natural history of HBV infection and interpreting serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
This concise MedicalMinute presentation reviews the AASLD guidelines on monitoring and treatment for patients with HBV infection, including a brief discussion of HCC risk in various patient populations.
Review key data and AASLD guideline recommendations on HCC risk, considerations for treatment, and optimal HCC monitoring.
This concise MedicalMinute presentation reviews the AASLD recommendations on methods to assess liver fibrosis and inflammation and data and guidance on translating test results into management decisions.
Review key data and AASLD guideline recommendations on methods to evaluate liver fibrosis and inflammation to guide management decisions for patients with HBV infection.
This concise MedicalMinute presentation reviews the AASLD recommendations for caring for pregnant women with chronic HBV infection, including considerations for monitoring, treatment indications, treatment options, and prophylaxis to prevent mother-to-child transmission.
Review key data and AASLD guideline recommendations on managing HBV infection during pregnancy, including treatment indications, treatment options, and prophylaxis to prevent mother-to-child transmission.
Patients with immune-tolerant hepatitis B often do not require treatment, but certain characteristics may change the treatment decision for an individual patient. Hear expert insights on when and why we treat certain immune-tolerant patients with HBV.